Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $253.30 | Total: $1,266.50 |
| 1 | 10 | $214.56 | Total: $2,145.60 |
| 1 | 25 | $181.78 | Total: $4,544.50 |
| 1 | 50 | $154.96 | Total: $7,748.00 |
| 1 | 100 | $134.10 | Total: $13,410.01 |
Overview
UK-240455 is a potent and selective N-methyl-D-aspartic acid (NMDA) glycine receptor antagonist with neuroprotective effects and improvements in motor function in Parkinson's disease models, making it a potential candidate for Parkinson's disease treatment.
Chemical Properties
| Molecular Formula | C11H11Cl2N3O5S |
| Molecular Weight | 368.19 |
| CAS Numbers | 178908-09-3 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | N(CCO)(S(C)(=O)=O)C1=C2C(=CC(Cl)=C1Cl)NC(=O)C(=O)N2 |
Storage and Handling
0C Short Term, -20C Long Term
References
Webster R, et al. Pharmacokinetics and disposition of a novel NMDA glycine site antagonist [UK-240,455] in rats, dogs and man. Xenobiotica. 2003;33[5] 541-560.